Literature DB >> 19200449

Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette-Guérin (BCG) Tokyo 172: a comparative study of BCG vaccine substrains.

Masaaki Seki1, Ikuro Honda, Isao Fujita, Ikuya Yano, Saburo Yamamoto, Akira Koyama.   

Abstract

To investigate the molecular characteristics of bacillus Calmette-Guérin (BCG) vaccines, the complete genomic sequence of Mycobacterium bovis BCG Tokyo 172 was determined, and the results were compared with those for BCG Pasteur and other M. tuberculosis complex. The genome of BCG Tokyo had a length of 4,371,711bp and contained 4033 genes, including 3950 genes coding for proteins (CDS). There were 18 regions of difference (showing differences of more than 20bp), 20 insertion or deletion (ins/del) mutations of less than 20bp, and 68 SNPs between the two BCG substrains. These findings are useful for better understanding of the genetic differences in BCG substrains due to in vitro evolution of BCG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200449     DOI: 10.1016/j.vaccine.2009.01.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

Review 1.  Phylogenetic framework and molecular signatures for the main clades of the phylum Actinobacteria.

Authors:  Beile Gao; Radhey S Gupta
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

2.  Thr270Ile in embC (Rv3793) is not a marker for ethambutol resistance in the Mycobacterium tuberculosis complex.

Authors:  Claudio U Köser; David K Summers; John A C Archer
Journal:  Antimicrob Agents Chemother       Date:  2011-04       Impact factor: 5.191

3.  Whole-genome sequences of four Mycobacterium bovis BCG vaccine strains.

Authors:  Yuanlong Pan; Xi Yang; Jia Duan; Na Lu; Andrea S Leung; Vanessa Tran; Yongfei Hu; Na Wu; Di Liu; Zhiming Wang; Xuping Yu; Chen Chen; Yuanyuan Zhang; Kanglin Wan; Jun Liu; Baoli Zhu
Journal:  J Bacteriol       Date:  2011-04-08       Impact factor: 3.490

Review 4.  Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis.

Authors:  Michael J Brennan; Bartholt Clagett; Hillary Fitzgerald; Vicki Chen; Ann Williams; Angelo A Izzo; Lewellys F Barker
Journal:  Vaccine       Date:  2012-03-03       Impact factor: 3.641

5.  A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice.

Authors:  Chun Wang; Zhenhua Chen; Ruiling Fu; Ying Zhang; Lingxia Chen; Li Huang; Jinjin Li; Chunwei Shi; Xionglin Fan
Journal:  Med Microbiol Immunol       Date:  2011-02-22       Impact factor: 3.402

6.  Lipid phenotype of two distinct subpopulations of Mycobacterium bovis Bacillus Calmette-Guerin Tokyo 172 substrain.

Authors:  Takashi Naka; Shinji Maeda; Mamiko Niki; Naoya Ohara; Saburo Yamamoto; Ikuya Yano; Jun-Ichi Maeyama; Hisashi Ogura; Kazuo Kobayashi; Nagatoshi Fujiwara
Journal:  J Biol Chem       Date:  2011-10-26       Impact factor: 5.157

7.  Genome sequence of Mycobacterium bovis BCG Moreau, the Brazilian vaccine strain against tuberculosis.

Authors:  Leonardo H F Gomes; Thomas D Otto; Erico A Vasconcellos; Patrícia M Ferrão; Renata M Maia; Aline S Moreira; Marcelo A Ferreira; Luiz R R Castello-Branco; Wim M Degrave; Leila Mendonça-Lima
Journal:  J Bacteriol       Date:  2011-10       Impact factor: 3.490

8.  Mosaic structure of Mycobacterium bovis BCG genomes as a representation of phage sequences' mobility.

Authors:  Olga L Voronina; Marina S Kunda; Ekaterina I Aksenova; Andrey N Semenov; Natalia N Ryzhova; Vladimir G Lunin; Alexandr L Gintsburg
Journal:  BMC Genomics       Date:  2016-12-28       Impact factor: 3.969

Review 9.  The current state of tuberculosis vaccines.

Authors:  David A Hokey; Ann Ginsberg
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

Review 10.  Horizontal gene transfers with or without cell fusions in all categories of the living matter.

Authors:  Joseph G Sinkovics
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.